Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 3,025 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
Interventions
Bendamustine, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, T-cell Receptor-engineered T-cells
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lymphoma
Interventions
keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy, cyclophosphamide, doxorubicin hydrochloride, mitoxantrone hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Stanford, California • Omaha, Nebraska
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer

NCT07925333
Conditions
Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin (IL-2), Tumor Resection
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Neuroendocrine Carcinoma of the Skin
Interventions
CMF regimen, cyclophosphamide, fluorouracil, methotrexate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Conditions
HIV
Interventions
SB-728-T
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 7 more
Conditions
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
Interventions
DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Augusta, Georgia • New York, New York + 3 more
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Conditions
AML, MDS
Interventions
NKR-2
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 1 more
Conditions
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
96
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, lomustine, mesna, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 22 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 29 more
Conditions
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, iC9/CAR.19/IL15-Transduced CB-NK Cells, AP1903
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
7 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions
Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose
Drug · Biological · Diagnostic Test + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more
Conditions
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 1Phase 2 Interventional Results available

Stem Cell Transplantation for Fanconi Anemia

NCT00167206
Conditions
Fanconi Anemia
Interventions
Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation, Cyclophosphamide, Fludarabine
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Day to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Sarcoma
Interventions
filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
7
States / cities
Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cyclophosphamide, DRibble vaccine, Imiquimod, GM-CSF, HPV vaccine
Drug · Biological
Lead sponsor
UbiVac
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Portland, Oregon
Conditions
Desmoplastic Small Round Cell Tumor
Interventions
Ramucirumab, Cyclophosphamide, Vinorelbine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Conditions
Leukemia
Interventions
Cyclophosphamide, Allogeneic Bone Marrow Transplantation, Autologous Bone Marrow Transplantation, Total Body Irradiation (TBI)
Drug · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Santa Rosa, California + 19 more
Active, not recruiting Phase 1 Interventional

T-Cell Therapy for Advanced Breast Cancer

NCT02792114
Conditions
Breast Cancer, Metastatic HER2-negative Breast
Interventions
Cyclophosphamide, Mesothelin-targeted T cells, AP1903
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Completed Phase 2 Interventional Results available

Phase II ABT-888 With Cyclophosphamide

NCT01306032
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions
ABT-888, Cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Davis, California • Tampa, Florida • Chicago, Illinois + 6 more
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Waldenstrom Macroglobulinemia
Interventions
Zanubrutinib, Bendamustine, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Boston, Massachusetts • Dallas, Texas
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more